Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Christine Walsh

Concepts (183)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Ovarian Neoplasms
18
2023
407
4.580
Why?
Endometrial Neoplasms
7
2022
151
2.020
Why?
Adenocarcinoma, Clear Cell
3
2016
14
1.150
Why?
BRCA2 Protein
3
2021
42
1.000
Why?
Neoplasms, Glandular and Epithelial
5
2017
39
0.950
Why?
BRCA1 Protein
2
2015
57
0.800
Why?
Myeloproliferative Disorders
1
2021
26
0.780
Why?
Cystadenocarcinoma, Serous
5
2016
44
0.770
Why?
Maintenance Chemotherapy
1
2020
22
0.750
Why?
Poly(ADP-ribose) Polymerase Inhibitors
2
2021
67
0.740
Why?
Indazoles
1
2020
58
0.720
Why?
Phthalazines
1
2020
39
0.720
Why?
Deoxycytidine
1
2021
140
0.720
Why?
Bevacizumab
1
2020
118
0.710
Why?
Neoplasm Staging
8
2021
1178
0.700
Why?
Cisplatin
1
2021
263
0.690
Why?
Piperidines
1
2020
163
0.670
Why?
Medical Oncology
2
2020
230
0.670
Why?
Tumor Suppressor Protein p53
1
2022
449
0.650
Why?
Piperazines
1
2020
314
0.620
Why?
Gynecology
1
2020
185
0.590
Why?
Fellowships and Scholarships
1
2020
241
0.590
Why?
Neoplasm Recurrence, Local
8
2021
863
0.570
Why?
Thromboplastin
1
2017
71
0.570
Why?
Antibodies, Monoclonal, Humanized
1
2021
667
0.560
Why?
Colorectal Neoplasms, Hereditary Nonpolyposis
2
2023
31
0.550
Why?
Genetic Testing
2
2017
382
0.530
Why?
Genital Neoplasms, Female
2
2015
73
0.520
Why?
Venous Thrombosis
1
2017
145
0.510
Why?
Antineoplastic Combined Chemotherapy Protocols
2
2021
1361
0.480
Why?
Cystadenocarcinoma, Papillary
2
2008
5
0.400
Why?
Adenocarcinoma, Papillary
1
2011
9
0.390
Why?
Polymorphism, Single Nucleotide
4
2014
1918
0.390
Why?
Biomarkers, Tumor
2
2022
1048
0.380
Why?
Genes, BRCA2
3
2023
26
0.380
Why?
Female
31
2023
59913
0.380
Why?
Genes, BRCA1
3
2023
33
0.380
Why?
Internship and Residency
1
2020
951
0.380
Why?
Ovariectomy
4
2023
117
0.380
Why?
Aged, 80 and over
13
2021
6417
0.370
Why?
Carcinoma, Endometrioid
1
2010
47
0.360
Why?
Aged
18
2021
19251
0.350
Why?
Venous Thromboembolism
1
2013
234
0.350
Why?
Middle Aged
20
2021
26999
0.340
Why?
DNA Repair
1
2011
190
0.340
Why?
Platinum
2
2021
40
0.330
Why?
Survival Rate
5
2021
1650
0.330
Why?
Uniparental Disomy
1
2008
7
0.330
Why?
Loss of Heterozygosity
1
2008
41
0.320
Why?
Homologous Recombination
2
2020
21
0.310
Why?
Neoplasms
1
2021
2118
0.300
Why?
CA-125 Antigen
2
2021
13
0.290
Why?
Humans
32
2023
115587
0.280
Why?
Antineoplastic Agents
1
2017
1893
0.280
Why?
Proto-Oncogene Proteins c-mdm2
1
2006
57
0.270
Why?
Prognosis
5
2022
3339
0.260
Why?
Neoplasms, Multiple Primary
1
2005
52
0.250
Why?
Adult
18
2021
30718
0.240
Why?
DNA-Binding Proteins
1
2011
1316
0.240
Why?
Molecular Targeted Therapy
2
2017
348
0.220
Why?
Neoplasms, Unknown Primary
1
2023
12
0.220
Why?
Disease-Free Survival
3
2013
621
0.210
Why?
Molecular Diagnostic Techniques
1
2022
91
0.200
Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
40
0.190
Why?
Mutation
3
2023
3364
0.190
Why?
Computing Methodologies
1
2020
2
0.190
Why?
Benzamides
1
2021
168
0.190
Why?
Survival Analysis
2
2017
1219
0.190
Why?
Breast Neoplasms
2
2023
1872
0.190
Why?
Thrombocytosis
2
2014
7
0.190
Why?
Genetic Predisposition to Disease
3
2023
2125
0.180
Why?
B7-H1 Antigen
1
2021
139
0.170
Why?
Immunohistochemistry
2
2017
1642
0.170
Why?
Drug Administration Schedule
1
2021
724
0.160
Why?
Antineoplastic Agents, Immunological
1
2020
154
0.160
Why?
DNA, Neoplasm
2
2011
157
0.160
Why?
United States
3
2020
12295
0.150
Why?
Carcinoma in Situ
2
2016
44
0.150
Why?
Cost-Benefit Analysis
1
2020
548
0.150
Why?
Enzyme Multiplied Immunoassay Technique
1
2017
2
0.150
Why?
Retrospective Studies
9
2016
12608
0.140
Why?
Uterine Neoplasms
2
2009
73
0.140
Why?
Genetic Counseling
1
2017
67
0.140
Why?
Remission Induction
1
2017
240
0.140
Why?
Drug Resistance, Neoplasm
1
2021
638
0.140
Why?
Salpingectomy
1
2016
13
0.140
Why?
Vaginal Neoplasms
1
2016
11
0.140
Why?
Peritoneal Neoplasms
1
2016
54
0.130
Why?
Case-Control Studies
2
2017
3022
0.130
Why?
Chemotherapy, Adjuvant
1
2016
334
0.130
Why?
Medicare
1
2020
666
0.130
Why?
Lymph Node Excision
1
2016
141
0.120
Why?
Treatment Outcome
4
2021
9159
0.120
Why?
Promoter Regions, Genetic
2
2010
1122
0.110
Why?
ATP-Binding Cassette Transporters
1
2014
123
0.110
Why?
Patient Satisfaction
1
2017
585
0.110
Why?
Time Factors
3
2021
6165
0.110
Why?
Adenocarcinoma
2
2011
799
0.110
Why?
Lymph Nodes
1
2016
423
0.110
Why?
Prefrontal Cortex
1
2016
267
0.110
Why?
Brain Mapping
1
2016
521
0.100
Why?
Health Care Reform
1
2013
92
0.100
Why?
Endometrial Hyperplasia
1
2011
15
0.100
Why?
Terminal Care
1
2015
212
0.100
Why?
Executive Function
1
2016
373
0.100
Why?
Progestins
1
2011
75
0.090
Why?
Los Angeles
1
2010
56
0.090
Why?
MutL Protein Homolog 1
1
2010
9
0.090
Why?
Microsatellite Instability
1
2010
32
0.090
Why?
Germ-Line Mutation
1
2010
131
0.080
Why?
Clinical Trials as Topic
1
2013
941
0.080
Why?
Polymerase Chain Reaction
1
2011
1000
0.080
Why?
Carcinoma, Papillary
1
2009
73
0.080
Why?
Hysterectomy
2
2007
118
0.080
Why?
Cell Line, Tumor
1
2015
2751
0.080
Why?
Conization
1
2007
1
0.070
Why?
Healthcare Disparities
1
2013
485
0.070
Why?
Gynecologic Surgical Procedures
1
2007
49
0.070
Why?
Adaptor Proteins, Signal Transducing
1
2010
374
0.070
Why?
Oligonucleotide Array Sequence Analysis
1
2008
746
0.070
Why?
Fertility
1
2007
131
0.070
Why?
Follow-Up Studies
3
2016
4440
0.070
Why?
Risk Factors
3
2023
8697
0.070
Why?
Incidence
3
2021
2335
0.060
Why?
DNA Methylation
1
2010
498
0.060
Why?
Nuclear Proteins
1
2010
594
0.060
Why?
Membrane Proteins
1
2011
1024
0.060
Why?
Uterine Cervical Neoplasms
1
2007
213
0.060
Why?
Neoplasm Grading
2
2016
244
0.060
Why?
Age Factors
1
2010
2907
0.060
Why?
Mass Screening
1
2010
1024
0.050
Why?
Cohort Studies
4
2016
4944
0.050
Why?
Algorithms
1
2010
1490
0.050
Why?
Practice Guidelines as Topic
1
2010
1405
0.050
Why?
Young Adult
2
2016
10470
0.050
Why?
Mammography
1
2021
107
0.050
Why?
California
1
2021
367
0.040
Why?
Early Detection of Cancer
1
2021
340
0.040
Why?
Population Surveillance
2
2013
395
0.040
Why?
Databases, Factual
1
2021
1138
0.040
Why?
Anisotropy
1
2016
62
0.030
Why?
Disease Progression
2
2016
2418
0.030
Why?
Heterozygote
1
2016
252
0.030
Why?
Diffusion Magnetic Resonance Imaging
1
2016
85
0.030
Why?
Models, Anatomic
1
2016
92
0.030
Why?
Factor Analysis, Statistical
1
2016
261
0.030
Why?
Electronic Health Records
1
2021
805
0.030
Why?
Lymphatic Metastasis
1
2016
276
0.030
Why?
Risk Reduction Behavior
1
2016
201
0.030
Why?
ATP Binding Cassette Transporter 1
1
2014
10
0.030
Why?
White Matter
1
2016
103
0.030
Why?
Memory, Short-Term
1
2016
224
0.030
Why?
Real-Time Polymerase Chain Reaction
1
2014
317
0.030
Why?
Attention
1
2016
394
0.030
Why?
Referral and Consultation
1
2017
646
0.030
Why?
Diagnosis, Differential
1
2016
1357
0.030
Why?
Hospice Care
1
2015
186
0.030
Why?
Advance Care Planning
1
2015
197
0.030
Why?
Kaplan-Meier Estimate
1
2014
815
0.020
Why?
Health Personnel
1
2017
581
0.020
Why?
Neuropsychological Tests
1
2016
919
0.020
Why?
Premenopause
1
2011
103
0.020
Why?
Predictive Value of Tests
1
2016
1805
0.020
Why?
Neoplastic Stem Cells
1
2014
331
0.020
Why?
Precancerous Conditions
1
2011
156
0.020
Why?
Cell Movement
1
2014
867
0.020
Why?
Gene Expression Regulation, Neoplastic
1
2014
1147
0.020
Why?
Carboplatin
1
2009
139
0.020
Why?
Brachytherapy
1
2009
104
0.020
Why?
Genome-Wide Association Study
1
2014
1217
0.020
Why?
Multivariate Analysis
1
2011
1440
0.020
Why?
Paclitaxel
1
2009
192
0.020
Why?
Parity
1
2007
99
0.020
Why?
RNA, Messenger
1
2014
2574
0.020
Why?
Medical Records
1
2007
157
0.020
Why?
Combined Modality Therapy
1
2009
1127
0.020
Why?
Surveys and Questionnaires
1
2017
4665
0.020
Why?
Reoperation
1
2007
525
0.020
Why?
Pregnancy Outcome
1
2007
336
0.020
Why?
Emergency Service, Hospital
1
2015
1829
0.010
Why?
Proportional Hazards Models
1
2006
1087
0.010
Why?
Pregnancy
1
2007
5548
0.010
Why?
Male
1
2016
55949
0.010
Why?
Walsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)